Vimarsana
Biggest News Aggregation in the World

Page 3 - Peter Hillmen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Peter Hillmen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Peter Hillmen Today - Breaking & Trending Today

Swedish Orphan Biovitrum AB: New data reinforce robust efficacy and safety profile of Aspaveli/Empaveli (pegcetacoplan) for PNH at the EHA2022 Congress - Vimarsana News

Swedish Orphan Biovitrum AB: New data reinforce robust efficacy and safety profile of Aspaveli/Empaveli (pegcetacoplan) for PNH at the EHA2022 Congress

Published: June 10, 2022

STOCKHOLM, June 10, 2022 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today reported new analyses of phase 3 studies

Source: finanznachrichten.de
Related Topics:
United StatesUnited KingdomNordrhein WestfalenSaudi ArabiaAspaveli EmpaveliEmpaveli AspaveliAnders UllmanKwong LeeIndirect Comparisons In Health Technology AppraisalEuropean Hematology AssociationSobi Investor Relations TeamEuropean Organisation For ResearchApellis Pharmaceuticals IncEuropean UnionValue In HealthHead Of Research DevelopmentApellis PharmaceuticalsChief Medical OfficerPeter HillmenEuropean OrganisationCancer QualityLife Questionnaire CorePopulation Adjusted Indirect ComparisonsHealth TechnologyMedical Decision Making
New data reinforce robust efficacy and safety profile of Aspaveli/Empaveli (pegcetacoplan) for PNH at the EHA2022 Congre - Vimarsana News

New data reinforce robust efficacy and safety profile of Aspaveli/Empaveli (pegcetacoplan) for PNH at the EHA2022 Congre

Published: June 10, 2022

STOCKHOLM, June 10, 2022 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) and Apellis...

Source: europapress.es
Related Topics:
Saudi ArabiaUnited StatesUnited KingdomAspaveli EmpaveliEmpaveli AspaveliAnders UllmanKwong LeeIndirect Comparisons In Health Technology AppraisalEuropean Hematology AssociationSobi Investor Relations TeamEuropean Organisation For ResearchApellis Pharmaceuticals IncEuropean UnionValue In HealthHead Of Research DevelopmentApellis PharmaceuticalsChief Medical OfficerPeter HillmenEuropean OrganisationCancer QualityLife Questionnaire CorePopulation Adjusted Indirect ComparisonsHealth TechnologyMedical Decision MakingAdjusted Indirect Comparisons
Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q1 2022 Results - Earnings Call Transcript - Vimarsana News

Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q1 2022 Results - Earnings Call Transcript

Published: May 5, 2022

Apellis Pharmaceuticals, Inc. (NASDAQ:NASDAQ:APLS) Q1 2022 Earnings Conference Call May 04, 2022, 16:30 ET Company Participants Meredith Kaya - SVP, IR & Strategic Finance Adam Townsend...

Source: seekingalpha.com
Related Topics:
United StatesJon MillerRaymond JamesTim SullivanEliana MerleMeredith KayaDerek ArchilaSteve SeedhouseMadam TownsendCedric FrancoisYigal NochomovitzLaura ChicoChris HowertonFederico GrossiMadhu KumarJonathan MillerColleen KusyTimur IvannikovPhilip NadeauTimothy SullivanCompany ParticipantsCiti GroupGoldman SachsApellis Pharmaceuticals First QuarterMeeting Of The American Society Gene
Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results - Vimarsana News

Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results

Published: May 4, 2022

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Related Topics:
Saudi ArabiaUnited StatesUnited KingdomCedric FrancoisMeredith KayaLissa PavlukExchange Commission OnSpark Therapeutics IncAdvisory Committee On Immunization PracticesExchange CommissionDevelopment Rd ExpensesApellis Pharmaceuticals IncEuropean UnionGeographic Atrophy Insights SurveyUpcoming MilestonesNocturnal HemoglobinuriaPeter HillmenHematology EngagementInvestigational New DrugSpark TherapeuticsNew Drug ApplicationHarris PollMarketing Authorization ApplicationSafety InformationAdvisory Committee
Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company - Vimarsana News

Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company

Published: May 3, 2022

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Related Topics:
Saudi ArabiaUnited StatesUnited KingdomCity OfGreat BritainCedric FrancoisMeredith KayaLissa PavlukLeeds National Commissioning Group Designated CentreExchange Commission OnLeeds Institute Of Medical ResearchInterest GroupMedicine At Leeds Medical SchoolAdvisory Committee On Immunization PracticesExchange CommissionApellis Pharmaceuticals IncLeeds Medical SchoolEuropean UnionGlobal Registry Executive CommitteePeter HillmenLeeds InstituteMedical ResearchRegistry Executive CommitteeNew England JournalHammersmith Hospital